Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue

 
• By Mandy Jackson

Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.

Scientist analyzes DNA gel used in genetics, forensics, drug discovery, biology and medicine.
Genomics and proteomics are helping Amgen R&D work more efficiently • Source: Shutterstock

More from Business

More from Scrip